Halper Sadeh LLC, a New York–based investor rights law firm, has initiated an investigation into the proposed sale of Lisata Therapeutics, Inc. to Kuva Labs, Inc. The inquiry will examine whether Lisata’s board of directors secured adequate consideration for shareholders in the transaction and complied with federal securities laws and fiduciary duties. Shareholders are encouraged to contact Halper Sadeh attorneys Daniel Sadeh or Zachary Halper at (212) 763-0060 or via email to explore their legal rights and options.

Under the binding term sheet, Kuva Labs will acquire all outstanding Lisata shares for $4.00 per share in cash. In addition, Lisata stockholders will receive two non-tradeable contingent value rights (CVRs): one CVR entitles holders to $1.00 per share upon the reversion of certepetide rights in Greater China within 12 months, while the second entitles holders to $1.00 per share upon the filing of a new drug application for certepetide. The combination of upfront cash and potential CVR payments implies a total consideration of up to $6.00 per share if both milestones are achieved.

The investigation focuses on whether Lisata’s board failed to seek the highest possible price, neglected to determine if Kuva’s offer undervalued the company’s clinical-stage pipeline, and omitted material information necessary for shareholders to fully assess the merger consideration. Halper Sadeh asserts that these potential omissions may constitute breaches of fiduciary duty and violations of disclosure requirements under U.S. securities laws.

On behalf of Lisata shareholders, Halper Sadeh LLC may pursue court-ordered relief including increased merger consideration, supplemental disclosures, or other benefits. The firm will handle any resulting action on a contingent fee basis, ensuring that shareholders incur no out-of-pocket legal expenses unless recovery is secured. Investors worldwide have benefited from Halper Sadeh’s prior successes in recovering millions of dollars for defrauded shareholders.